(CBMG) |
| 0 (0%) 05-31 07:51 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 35.10 |
| Resistance 1: | 33.77 |
| Pivot price: | 32.58 |
| Support 1: | 31.63 |
| Support 2: | 26.32 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 1.090 |
| Book Value | 1.870 |
| PEG Ratio | 1.73 |
| Gross Profit | 3.758 |
| Profit Margin (%) | 11.96 |
| Operating Margin (%) | 13.27 |
| Return on Assets (ttm) | 13.5 |
| Return on Equity (ttm) | 49.2 |
Company news
Tue, 20 Jan 2026
AstraZeneca pays $630m to get full control of AbelZeta CAR-T - pharmaphorum
Thu, 04 May 2023
Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies - PMLiVE
Thu, 04 May 2023
J&J forks out $245m to develop CAR-T therapies - BioProcess International
Wed, 03 May 2023
Janssen Biotech signs licence deal with CBMG for CAR-T cancer therapies - Pharmaceutical Technology
Wed, 03 May 2023
May 2 Quick Takes: Janssen paying CBMG $245M for CAR T rights - BioCentury
Tue, 02 May 2023
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies - BioSpace
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
